Trinity Biotech PLC (TRIB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 0.22. The fair price of Trinity Biotech PLC (TRIB) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 0.72 USD , Trinity Biotech PLC By Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：0.72

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Trinity Biotech PLC (TRIB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Trinity Biotech PLC (TRIB) has a current Price-to-Book (P/B) ratio of -0.28. Compared to its 3-year average P/B ratio of -1.65, the current P/B ratio is approximately -83.01% higher. Relative to its 5-year average P/B ratio of -37.14, the current P/B ratio is about -99.24% higher. Trinity Biotech PLC (TRIB) has a Forward Free Cash Flow (FCF) yield of approximately -37.71%. Compared to its 3-year average FCF yield of -50.22%, the current FCF yield is approximately -24.92% lower. Relative to its 5-year average FCF yield of -18.41%, the current FCF yield is about 104.81% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TRIB competitors is 2.00, providing a benchmark for relative valuation. Trinity Biotech PLC Corp (TRIB.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of 3.24%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TRIB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TRIB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TRIB currently overvalued or undervalued?

What is Trinity Biotech PLC (TRIB) fair value?

TRIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Trinity Biotech PLC (TRIB) is between +Inf to +Inf according to relative valuation method.

How does TRIB's valuation metrics compare to the industry average?

The average P/S ratio for TRIB's competitors is 2.00, providing a benchmark for relative valuation. Trinity Biotech PLC Corp (TRIB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 3.24%, this premium appears unsustainable.

What is the current P/B ratio for Trinity Biotech PLC (TRIB) as of Mar 02 2026?

As of Mar 02 2026, Trinity Biotech PLC (TRIB) has a P/B ratio of -0.28. This indicates that the market values TRIB at -0.28 times its book value.

What is the current FCF Yield for Trinity Biotech PLC (TRIB) as of Mar 02 2026?

As of Mar 02 2026, Trinity Biotech PLC (TRIB) has a FCF Yield of -37.71%. This means that for every dollar of Trinity Biotech PLC's market capitalization, the company generates -37.71 cents in free cash flow.

What is the current Forward P/E ratio for Trinity Biotech PLC (TRIB) as of Mar 02 2026?

As of Mar 02 2026, Trinity Biotech PLC (TRIB) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Trinity Biotech PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Trinity Biotech PLC (TRIB) as of Mar 02 2026?

As of Mar 02 2026, Trinity Biotech PLC (TRIB) has a Forward P/S ratio of 0.00. This means the market is valuing TRIB at $0.00 for every dollar of expected revenue over the next 12 months.

TRIB Valuation